Pan-cancer Analysis Reveals CCL5/CSF2 As Potential Predictive Biomarkers for Immune Checkpoint Inhibitors

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2024 Sep 10

PMID 39256838

Authors

Yi-Chao Chen

Wei-Zhong Zheng

Chun-Peng Liu

Yong-Qiang Zhao

Jun-Wei Li

Ze-Sen Du

Tian-Tian Zhai

Hao-Yu Lin

Wen-Qi Shi

Shan-Qing Cai

Feng Pan

Si-Qi Qiu

Affiliations

Soon will be listed here.

Abstract

Background: Currently, there are no optimal biomarkers available for distinguishing patients who will respond to immune checkpoint inhibitors (ICIs) therapies. Consequently, the exploration of novel biomarkers that can predict responsiveness to ICIs is crucial in the field of immunotherapy.

Methods: We estimated the proportions of 22 immune cell components in 10 cancer types (6,128 tumors) using the CIBERSORT algorithm, and further classified patients based on their tumor immune cell proportions in a pan-cancer setting using k-means clustering. Differentially expressed immune genes between the patient subgroups were identified, and potential predictive biomarkers for ICIs were explored. Finally, the predictive value of the identified biomarkers was verified in patients with urothelial carcinoma (UC) and esophageal squamous cell carcinoma (ESCC) who received ICIs.

Results: Our study identified two subgroups of patients with distinct immune infiltrating phenotypes and differing clinical outcomes. The patient subgroup with improved outcomes displayed tumors enriched with genes related to immune response regulation and pathway activation. Furthermore, CCL5 and CSF2 were identified as immune-related hub-genes and were found to be prognostic in a pan-cancer setting. Importantly, UC and ESCC patients with high expression of CCL5 and low expression of CSF2 responded better to ICIs.

Conclusion: We demonstrated CCL5 and CSF2 as potential novel biomarkers for predicting the response to ICIs in patients with UC and ESCC. The predictive value of these biomarkers in other cancer types warrants further evaluation in future studies.

References

Divella R, De Palma G, Tufaro A, Pelagio G, Gadaleta-Caldarola G, Bringiotti R . Diet, Probiotics and Physical Activity: The Right Allies for a Healthy Microbiota. Anticancer Res. 2021; 41(6):2759-2772. DOI: 10.21873/anticanres.15057. View

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

Gentles A, Newman A, Liu C, Bratman S, Feng W, Kim D . The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015; 21(8):938-945. PMC: 4852857. DOI: 10.1038/nm.3909. View

Rizzo A, Ricci A, Lanotte L, Lombardi L, Di Federico A, Brandi G . Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opin Investig Drugs. 2021; 31(6):557-565. DOI: 10.1080/13543784.2022.2009456. View

Guven D, Sahin T, Erul E, Cakir I, Ucgul E, Yildirim H . The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. J Clin Med. 2022; 11(15). PMC: 9369683. DOI: 10.3390/jcm11154523. View

Rouquette I, Taranchon-Clermont E, Gilhodes J, Bluthgen M, Perallon R, Chalabreysse L . Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. Biomark Res. 2019; 7:28. PMC: 6894111. DOI: 10.1186/s40364-019-0177-8. View

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J . Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018; 362(6411). PMC: 6718162. DOI: 10.1126/science.aar3593. View

Camp R, Dolled-Filhart M, Rimm D . X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10(21):7252-9. DOI: 10.1158/1078-0432.CCR-04-0713. View

Wakiyama H, Masuda T, Motomura Y, Hu Q, Tobo T, Eguchi H . Cytolytic Activity (CYT) Score Is a Prognostic Biomarker Reflecting Host Immune Status in Hepatocellular Carcinoma (HCC). Anticancer Res. 2018; 38(12):6631-6638. DOI: 10.21873/anticanres.13030. View

10.

Barbi J, Pardoll D, Pan F . Treg functional stability and its responsiveness to the microenvironment. Immunol Rev. 2014; 259(1):115-39. PMC: 3996455. DOI: 10.1111/imr.12172. View

11.

El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088):2492-2502. PMC: 7539326. DOI: 10.1016/S0140-6736(17)31046-2. View

12.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

13.

Hollern D, Xu N, Thennavan A, Glodowski C, Garcia-Recio S, Mott K . B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. Cell. 2019; 179(5):1191-1206.e21. PMC: 6911685. DOI: 10.1016/j.cell.2019.10.028. View

14.

Dinh H, Pan F, Wang G, Huang Q, Olingy C, Wu Z . Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment. Nat Commun. 2021; 12(1):7335. PMC: 8683407. DOI: 10.1038/s41467-021-27599-5. View

15.

Xiong Y, Wang K, Zhou H, Peng L, You W, Fu Z . Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression-based study. Cancer Med. 2018; 7(9):4496-4508. PMC: 6144159. DOI: 10.1002/cam4.1745. View

16.

Helmink B, Reddy S, Gao J, Zhang S, Basar R, Thakur R . B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020; 577(7791):549-555. PMC: 8762581. DOI: 10.1038/s41586-019-1922-8. View

17.

Forde P, Chaft J, Smith K, Anagnostou V, Cottrell T, Hellmann M . Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018; 378(21):1976-1986. PMC: 6223617. DOI: 10.1056/NEJMoa1716078. View

18.

Nanda R, Chow L, Dees E, Berger R, Gupta S, Geva R . Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016; 34(21):2460-7. PMC: 6816000. DOI: 10.1200/JCO.2015.64.8931. View

19.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

20.

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View